Showing results (691-700 of 1,033) with videos related to
Sort By:
Pageof 104
The Lancet. Respiratory Medicine|March 16, 2015
Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE studyR Gisli Jenkins, Juliet K Simpson, Gauri Saini, et al.The Lancet. Respiratory Medicine|April 9, 2021
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 studyTimothy A Yap, Kazuhiko Nakagawa, Nobukazu Fujimoto, et al.The Lancet. Respiratory Medicine|April 12, 2021
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trialSanjay Ramakrishnan, Dan V Nicolau, Beverly Langford, et al.The Lancet. Respiratory Medicine|April 27, 2023
Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)James D Chalmers, Eva Polverino, Megan L Crichton, et al.The Lancet. Respiratory Medicine|July 21, 2020
Lung recruitment before surfactant administration in extremely preterm neonates with respiratory distress syndrome (IN-REC-SUR-E): a randomised, unblinded, controlled trialGiovanni Vento, Maria Luisa Ventura, Roberta Pastorino, et al.The Lancet. Respiratory Medicine|March 5, 2015
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trialsMario Castro, James Zangrilli, Michael E Wechsler, et al.The Lancet. Respiratory Medicine|March 17, 2015
Non-tuberculous mycobacteria in children: muddying the waters of tuberculosis diagnosisElisa López-Varela, Alberto L García-Basteiro, Begoña Santiago, et al.The Lancet. Respiratory Medicine|January 28, 2014
Mortality trends in chronic obstructive pulmonary disease in Europe, 1994-2010: a joinpoint regression analysisJose Luis López-Campos, Miguel Ruiz-Ramos, Joan B SorianoThe Lancet. Respiratory Medicine|January 28, 2014
Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trialHenrik Watz, Helen Barnacle, Benjamin F Hartley, et al.The Lancet. Respiratory Medicine|June 6, 2014
Unlocking the quiet zone: the small airway asthma phenotypeBrian Lipworth, Arvind Manoharan, William AndersonPageof 104